Company profile
BeBetter Med
China clinical-stage biopharma -- oncology, autoimmune, metabolic disease
688759 · SSE STAR Market · China
Public Market Listing
688759SSE STAR Market
Live quotes, historical charts, and market capitalization for BeBetter Med are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CDK4 (selective)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | PI3K and HDAC (dual inhibition)Small molecule | Multiple Myeloma | |
| Phase 2 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | Angiotensinogen (AGT) / PCSK9 (dual)RNA / oligonucleotide | Hypertension |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.